Almazrou, 161 patient HCQ late treatment study: 65% lower ventilation [p=0.16] and 21% lower ICU admission [p=0.78] https://c19p.org/almazrou
copied to clipboard
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study
et al., Saudi Pharmaceutical Journal, doi:10.1016/j.jsps.2020.09.019
Retrospective 161 hospitalized patients in Saudi Arabia showing lower ventilation and ICU admission with HCQ, but not statistically significant with the small sample sizes.
|
risk of mechanical ventilation, 65.0% lower, RR 0.35, p = 0.16, treatment 3 of 95 (3.2%), control 6 of 66 (9.1%), NNT 17.
|
|
risk of ICU admission, 21.0% lower, RR 0.79, p = 0.78, treatment 8 of 95 (8.4%), control 7 of 66 (10.6%), NNT 46.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Almazrou et al., 10/1/2020, retrospective, Saudi Arabia, Middle East, peer-reviewed, 5 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.